Production (Stage)
E
Adial Pharmaceuticals, Inc. ADIL
$0.6898 -$0.0292-4.06% NASDAQ
Recommendation
Prev Close
$0.719
Volume
96,963
Avg Vol (90D)
937,680
Market Cap
$4.73M
Dividend & Yield
--
52-Week Range
$0.5704 - $3.00
P/E (TTM)
--
EPS (TTM)
-$3.48
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update ...
5/15/2025 - GuruFocus
Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
5/15/2025 - GuruFocus
Adial Pharmaceuticals (ADIL) Reports Q1 2025 Results ADIL Stock News
5/15/2025 - GuruFocus
Adial Pharmaceuticals expects cash to fund operations into Q4 of 2025
5/15/2025 - The Fly
Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
5/15/2025 - Globe Newswire
Adial Pharmaceuticals (ADIL) Receives Milestone Payment for Asthma Drug Development ADIL ...
5/13/2025 - GuruFocus
Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study
5/13/2025 - GuruFocus
Adial Pharmaceuticals receives milestone payment from Adovate
5/13/2025 - The Fly
Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study
5/13/2025 - Globe Newswire
Critical Contrast: Adial Pharmaceuticals (NASDAQ:ADIL) vs. Immune Pharmaceuticals (OTCMKTS:IMNPQ)
5/10/2025 - Ticker Report
Adial Pharmaceuticals (ADIL) Receives FDA Green Light for Phase 3 Meeting ADIL Stock News
5/8/2025 - GuruFocus
Adial Pharmaceuticals announces FDA granted request for End of Phase 2 meeting
5/8/2025 - The Fly
Adial Pharmaceuticals Granted End of Phase 2 Meeting from the U.S. Food and Drug Administration
5/8/2025 - Globe Newswire
EXCLUSIVE: Adial Pharmaceuticals Secures FDA End of Phase 2 Meeting Request To Discuss Upcoming Clinical Development Plan For Lead Program
5/8/2025 - Benzinga
Adial Pharmaceuticals raises $2.75M
5/7/2025 - Bizjournals.com - Health Care News
ADIL: Adial Pharmaceuticals Boosts Patent Portfolio with New Approval ADIL Stock News
5/5/2025 - GuruFocus
Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds
5/2/2025 - GuruFocus
Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds
5/2/2025 - GuruFocus
Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2. ...
5/2/2025 - GuruFocus
Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds
5/2/2025 - Globe Newswire
Retail Traders Flock To Adial Pharma After Patent News Sends Shares Soaring
5/2/2025 - Stocktwits News Feed
Adial Pharmaceuticals Expands Intellectual Property Portfolio with New U.S. ...
5/1/2025 - GuruFocus
Adial Pharmaceuticals (ADIL) Secures Patent for Novel Addiction Treatment Method ADIL Stock News
5/1/2025 - GuruFocus
Adial Pharmaceuticals expands intellectual property with new U.S. patent
5/1/2025 - The Fly
Adial Pharmaceuticals Expands Intellectual Property Portfolio with New U.S. Patent Granted for Genetic-Based Treatment of Alcohol and Opioid Use Disorders
5/1/2025 - Globe Newswire
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$8.28M
EBIT (TTM)
-$8.28M
Net Income (TTM)
-$13.20M
Balance Sheet
Total Assets (Q)
$5.04M
Total Debt (Q)
$0.00
Total Liabilities (Q)
$975.90K
Book Value Per Share (Q)
$0.6283
Cash Flow
Cash from Operations (TTM)
-$6.92M
Cash from Investing (TTM)
--
Cash from Financing (TTM)
$7.85M
Net Change in Cash (TTM)
$923.40K
Filings
Filing Date
Tuesday, March 4, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 12 and 16 (est)
Price History
Loading...
Beta
0.79
7-Day Total Return
6.12%
30-Day Total Return
-3.54%
60-Day Total Return
-10.42%
90-Day Total Return
-32.37%
Year to Date Total Return
-34.96%
1-Year Total Return
-44.82%
2-Year Total Return
-90.88%
3-Year Total Return
-97.99%
5-Year Total Return
-98.28%
52-week Low
May 09, 2025 - $0.5704
52-week High
Jul 23, 2024 - $3.00
Valuation
Market Cap
$4.73M - Nano Cap
Enterprise Value
$2.36M
Price/Sales (TTM)
--
Price/Book (Q)
1.14
Dividends and Shares
Shares Outstanding
6.42M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.adial.com
Phone Number
(804) 487-8196
Address
4870 Sadler Road
Glen Allen, VA 23060
Country
United States
Year Founded
2010
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The... more
NASDAQ 05/23/2025 4:00PM Eastern Quotes delayed